How obesity treatment patients at Nîmes Hospital may show misuse of alcohol and other addictions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study explores the relationship between obesity management and the development of addictive behaviors, including alcohol misuse, among adults receiving care at the Nîmes University Hospital endocrinology and obesity clinics. The researchers will collect data from blood tests and clinical information to describe patterns and potential transfers from eating disorders to substance use after obesity treatment, including bariatric surgery. The goal is to better understand whether shifts in behavior occur in this patient group and identify factors that may influence risk. Participation is limited to adults newly managed at the CHU de Nîmes obesity clinic who meet eligibility criteria, with several common exclusions to ensure informed consent and safety. No intervention beyond standard care and data collection is described.

Why it matters

Who can join: the full rules

* Patient being managed for the first time at Nîmes University Hospital Obesity Clinic ( complete hospitalization, outpatients' or consultation).
* Patient being managed for obesity defined by a body mass index (BMI) of 30 kg.m-² or over
* Patient affiliated to or covered by a health insurance scheme.
* Adult patient (≥ 18 years).

Exclusion Criteria:

* Patient with psychiatric disorder reducing capacity for comprehension.
* Patient in an exclusion period determined by another study.
* Patient under legal guardianship, tutorship or curatorship.
* Patient to whom it is impossible to give clear information
* Patient who is pregnant, about to give birth or breastfeeding.

Where it's running

• CHU de Nimes
  Nîmes, France Recruiting

Study contacts

• Study coordinator: Emma LUCQUIAUD, Dr.
• Email: emma.lucquiaud@chu-nimes.fr
• Phone: +33 4.66.68.33.21

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.